Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1995 Jul;74(1):14–17. doi: 10.1136/hrt.74.1.14

Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.

M D Feher 1, J Foxton 1, D Banks 1, A F Lant 1, R Wray 1
PMCID: PMC483939  PMID: 7662446

Abstract

OBJECTIVE--To evaluate the long-term safety profile of treatment with a statin-fibrate combination in a cohort of patients with documented coronary artery disease. DESIGN--Retrospective cohort analytical study. SETTING--District general hospital. PATIENTS--102 (81 male and 21 female) hypercholesterolaemic (total cholesterol concentration > 6.5 mmol/l) patients with documented coronary artery disease and who had been treated with a statin-fibrate combination for over 1 year. Coronary artery disease was confirmed by angiography in 93 patients and by a positive (Bruce protocol) exercise test in the remainder. Fifty eight patients had a history of previous coronary bypass graft surgery. INTERVENTIONS--Twice daily lipid lowering treatment was given, with the fibrate administered in the morning (either bezafibrate 400 mg (n = 101) or fenofibrate 200 mg (n = 1)) and the statin in the evening (either simvastatin 10 mg (n = 23), 20 mg (n = 72), or 40 mg (n = 2) or pravastatin 10 mg (n = 1) or 20 mg (n = 4)). Treatment continued for 1 (n = 9), 2 (n = 58), or 3 (n = 35) years. MAIN OUTCOME MEASURES--Selected laboratory variables (total cholesterol concentration and liver (aspartate transaminase (AST)) and muscle enzyme (creatine kinase (CK)) activities) and documented symptomatology. RESULTS--A mean (SD) total cholesterol concentration of 5.2 (0.8) mmol/l was achieved after combined treatment for 1 year which was maintained at annual follow up. Over a maximum 3 year follow up no patient reported myalgic symptoms and none had a measured CK activity > 10 times above nomal. Four men on a simvastatin-bezafibrate combination had a CK activity rise to less than three times normal. Fourteen patients with a negative history of alcohol excess (consumption < 21 units/week) had borderline raised AST values. CONCLUSIONS--Statin-fibrate combination treatment for up to 3 years in a cohort of patients with coronary artery disease was not associated with serious disturbances in biochemical markers of muscle or liver function.

Full text

PDF
14

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayanian J. Z., Fuchs C. S., Stone R. M. Lovastatin and rhabdomyolysis. Ann Intern Med. 1988 Oct 15;109(8):682–683. doi: 10.7326/0003-4819-109-8-682. [DOI] [PubMed] [Google Scholar]
  2. Berland Y., Vacher Coponat H., Durand C., Baz M., Laugier R., Musso J. L. Rhabdomyolysis with simvastatin use. Nephron. 1991;57(3):365–366. doi: 10.1159/000186289. [DOI] [PubMed] [Google Scholar]
  3. Betteridge D. J., Dodson P. M., Durrington P. N., Hughes E. A., Laker M. F., Nicholls D. P., Rees J. A., Seymour C. A., Thompson G. R., Winder A. F. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J. 1993 May;69(811):359–369. doi: 10.1136/pgmj.69.811.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bhatnagar D., Durrington P. N., Neary R., Miller J. P. Elevation of skeletal muscle isoform of serum creatine kinase in heterozygous familial hypercholesterolaemia. J Intern Med. 1990 Nov;228(5):493–495. doi: 10.1111/j.1365-2796.1990.tb00268.x. [DOI] [PubMed] [Google Scholar]
  5. Blane G. F. Review of European clinical experience with fenofibrate. Cardiology. 1989;76 (Suppl 1):1–13. doi: 10.1159/000174541. [DOI] [PubMed] [Google Scholar]
  6. Corpier C. L., Jones P. H., Suki W. N., Lederer E. D., Quinones M. A., Schmidt S. W., Young J. B. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA. 1988 Jul 8;260(2):239–241. [PubMed] [Google Scholar]
  7. Crouse J. R., 3rd Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med. 1987 Aug;83(2):243–248. doi: 10.1016/0002-9343(87)90692-9. [DOI] [PubMed] [Google Scholar]
  8. East C., Alivizatos P. A., Grundy S. M., Jones P. H., Farmer J. A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988 Jan 7;318(1):47–48. doi: 10.1056/NEJM198801073180111. [DOI] [PubMed] [Google Scholar]
  9. East C., Bilheimer D. W., Grundy S. M. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 1988 Jul 1;109(1):25–32. doi: 10.7326/0003-4819-109-1-25. [DOI] [PubMed] [Google Scholar]
  10. Grundy S. M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988 Jul 7;319(1):24–33. doi: 10.1056/NEJM198807073190105. [DOI] [PubMed] [Google Scholar]
  11. Horsmans Y., Desager J. P., Harvengt C. Effects of combined bezafibrate-simvastatin appraised in healthy subjects. J Clin Pharmacol. 1992 May;32(5):422–426. doi: 10.1002/j.1552-4604.1992.tb03857.x. [DOI] [PubMed] [Google Scholar]
  12. Illingworth D. R., O'Malley J. P. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism. 1990 Apr;39(4):403–409. doi: 10.1016/0026-0495(90)90256-c. [DOI] [PubMed] [Google Scholar]
  13. Leitersdorf E., Muratti E. N., Eliav O., Meiner V., Eisenberg S., Dann E. J., Sehayek E., Peters T. K., Stein Y. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. Am J Med. 1994 May;96(5):401–407. doi: 10.1016/0002-9343(94)90165-1. [DOI] [PubMed] [Google Scholar]
  14. Lintott C. J., Scott R. S., Sharpe D. N., Nye E. R., Charleson H., French J. K., White H. D., Reuben S., Maling T. J., Lewis G. R. Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation. Med J Aust. 1991 Oct 7;155(7):433–436. [PubMed] [Google Scholar]
  15. Maher V. M., Thompson G. R. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin. Q J Med. 1990 Feb;74(274):165–175. [PubMed] [Google Scholar]
  16. Marais G. E., Larson K. K. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med. 1990 Feb 1;112(3):228–230. doi: 10.7326/0003-4819-112-3-228. [DOI] [PubMed] [Google Scholar]
  17. Monk J. P., Todd P. A. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs. 1987 Jun;33(6):539–576. doi: 10.2165/00003495-198733060-00002. [DOI] [PubMed] [Google Scholar]
  18. Pierce L. R., Wysowski D. K., Gross T. P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990 Jul 4;264(1):71–75. [PubMed] [Google Scholar]
  19. Reaven P., Witztum J. L. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 1988 Oct 1;109(7):597–598. doi: 10.7326/0003-4819-109-7-597_2. [DOI] [PubMed] [Google Scholar]
  20. Rossouw J. E., Lewis B., Rifkind B. M. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990 Oct 18;323(16):1112–1119. doi: 10.1056/NEJM199010183231606. [DOI] [PubMed] [Google Scholar]
  21. Todd P. A., Goa K. L. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1990 Oct;40(4):583–607. doi: 10.2165/00003495-199040040-00007. [DOI] [PubMed] [Google Scholar]
  22. Wiklund O., Angelin B., Bergman M., Berglund L., Bondjers G., Carlsson A., Lindén T., Miettinen T., Odman B., Olofsson S. O. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993 Jan;94(1):13–20. doi: 10.1016/0002-9343(93)90114-5. [DOI] [PubMed] [Google Scholar]
  23. Yeshurun D., Abukarshin R., Elias N., Lanir A., Naschitz J. E. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. Clin Ther. 1993 Mar-Apr;15(2):355–363. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES